Pieris Pharmaceuticals, Inc. (PIRS) Financial Statements (2023 and Earlier)

Company Profile

Business Address 255 STATE STREET
BOSTON, MA 02109
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments117,76470,436104,154128,10772,62929,35629,349
Cash and cash equivalents117,76470,43662,26074,86737,87829,35629,349
Short-term investments  41,89453,24034,751  
Receivables3,3131,7066,7872,70115,54658 
Deferred costs  1,0053,374 1,279 
Other undisclosed current assets6,5483,5793,0671,2001,6151,9802,311
Total current assets:127,62575,721115,013135,38289,79032,67331,661
Noncurrent Assets
Operating lease, right-of-use asset3,9093,934 
Property, plant and equipment19,12222,04619,5025,0494,0342,2642,163
Long-term investments and receivables    9,922  
Long-term investments    9,922  
Other noncurrent assets2,9043,3093,146910130126127
Other undisclosed noncurrent assets  3,436    
Total noncurrent assets:25,93529,28926,0845,95914,0862,3902,290
TOTAL ASSETS:153,560105,010141,097141,341103,87635,06333,950
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15,5636,00115,74712,4648,6226,1062,798
Accounts payable8,6091,7875,8033,3502,4522,3861,059
Accrued liabilities3,3731,4559,9449,1146,1703,7191,739
Employee-related liabilities3,5812,759     
Deferred revenue25,11612,627 
Deferred revenue and credits35,61237,1532,275 
Contract with customer, liability11,256 
Other undisclosed current liabilities9,8823,517     
Total current liabilities:50,56122,14527,00348,07645,7758,3802,798
Noncurrent Liabilities
Long-term debt and lease obligation13,84115,932     
Operating lease, liability13,84115,932 
Liabilities, other than long-term debt38,40335,90647,25853,33046,5791,45624
Deferred revenue and credits53,30346,5421,409 
Accounts payable and accrued liabilities      24
Deferred revenue38,40335,900 
Contract with customer, liability47,258 
Other liabilities 6 273747 
Other undisclosed noncurrent liabilities  15,484    
Total noncurrent liabilities:52,24451,83862,74253,33046,5791,45624
Total liabilities:102,80573,98389,745101,40692,3549,8362,822
Stockholders' equity
Stockholders' equity attributable to parent50,75531,02751,35239,93511,52225,22731,128
Preferred stock     0 
Common stock72565554454340
Additional paid in capital306,998242,672227,468189,929136,484129,350112,227
Accumulated other comprehensive income (loss)829(295)(1,995)(2,982)(4,695)(1,501)(1,273)
Accumulated deficit(257,144)(211,406)(174,176)(147,066)(120,312)(102,665)(79,866)
Total stockholders' equity:50,75531,02751,35239,93511,52225,22731,128
TOTAL LIABILITIES AND EQUITY:153,560105,010141,097141,341103,87635,06333,950

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues31,41829,32346,27929,10125,2755,8312,932
Revenue, net26,76811,2992,736388
Gross profit:31,41829,32346,27929,10125,2755,8312,932
Operating expenses(83,249)(63,244)(73,436)(59,932)(39,869)(28,590)(16,613)
Operating loss:(51,831)(33,921)(27,157)(30,831)(14,594)(22,759)(13,681)
Nonoperating income (expense)2,404(3,648)353,432(2,258)12011
Investment income, nonoperating   1,651   
Foreign currency transaction gain (loss), before tax 861(22)(156)  
Other nonoperating income (expense)2,404(3,656)(26)1,803(2,102)12011
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes 5031,6533333082(185)
Loss from continuing operations before equity method investments, income taxes:(49,427)(37,066)(25,469)(27,066)(16,544)(22,637)(13,855)
Other undisclosed income from continuing operations before income taxes3,689    0 
Loss from continuing operations before income taxes:(45,738)(37,066)(25,469)(27,066)(16,544)(22,637)(13,855)
Income tax expense (benefit) (164) 312(1,103)(162)(204)
Net loss attributable to parent:(45,738)(37,230)(25,469)(26,754)(17,647)(22,799)(14,059)
Other undisclosed net loss available to common stockholders, basic  (2,830)    
Net loss available to common stockholders, diluted:(45,738)(37,230)(28,299)(26,754)(17,647)(22,799)(14,059)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(45,738)(37,230)(25,469)(26,754)(17,647)(22,799)(14,059)
Other comprehensive loss   (164)   
Comprehensive loss:(45,738)(37,230)(25,469)(26,918)(17,647)(22,799)(14,059)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1,1241,7009871,877(3,194)(229)(429)
Comprehensive loss, net of tax, attributable to parent:(44,614)(35,530)(24,482)(25,041)(20,841)(23,028)(14,488)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: